Close Menu

NEW YORK – The UK's National Institute for Health and Care Excellence has published a draft guidance recommending approval of olaparib (AstraZeneca's Lynparza) as a maintenance treatment for patients with BRCA1/2 mutation-positive, advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to first-line platinum chemotherapy. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sep
16

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.